GSK Plc reported better-than-expected profit in the first quarter, with sales from its asthma and HIV drugs offsetting a ...

GSK posted higher profit as sales for its specialty treatments for HIV, cancer and asthma beat expectations, offsetting lower ...

More children stopped using steroid inhalers to control their asthma after GlaxoSmithKline withdrew Flovent from the market.

WEDNESDAY, April 30, 2025 (HealthDay News) — More children stopped using steroid inhalers to control their asthma after a ...

GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...

GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks ...

GSK (GSK) stock gains as the company's Q1 2025 results beat Street forecasts thanks to its Specialty Medicines business. Read ...

GSK will use technologies including artificial intelligence to improve its productivity as a means of compensating for the potential financial hit from US tariffs on the pharmaceutical sector.

Data from the NERO study was presented at the American Association of Cancer Research (AACR) Annual Meeting 2025.

GSK is 'well positioned' to deal with the potential implications of any new US tariffs on pharma imports, the group said on ...

In its update, GSK reported a 17% rise in speciality medicines across its HIV, cancer and respiratory business to £2.93 ...